Supply Chain Intelligence

Spero Therapeutics, Inc. Supply Chain

SPRO supply chain intelligence for Spero Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SPRO ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

0Suppliers
7Customers
2Debt Items
20Related Chains

Spero Therapeutics, Inc. Suppliers

No suppliers on recordSpero Therapeutics, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Spero Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES 95% USAspending awards from Department of Health and Human Services: $60,234,832 across 2 awards. 75A50118C00015 IGF::OT::IGF; 75N93021C00022 TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBI…
PFE Pfizer Inc. 90% Reciprocal relationship from PFE graph: Reciprocal relationship from SPRO graph: In the third quarter of 2022, upon the completion of a milestone related to regulatory engagement for SPR206, Pfizer c…
PFE Pfizer Inc. 90% In the third quarter of 2022, upon the completion of a milestone related to regulatory engagement for SPR206, Pfizer communicated its approval that the milestone was achieved, and the Company receive…
GLAXO-GROUP-LIMITED GLAXO-GROUP-LIMITED 85% contract inception, the total transaction price was $ 64.7 million, which included the initial payment of $ 66.0 million in the fourth quarter of 2022 and the discount of $ 1.3 million related to the…
GSK GSK plc 85% Reciprocal relationship from GSK graph: Reciprocal relationship from SPRO graph: contract inception, the total transaction price was $ 64.7 million, which included the initial payment of $ 66.0 milli…
VRTX Vertex Pharmaceuticals Incorporated 72% Reciprocal relationship from VRTX graph: Reciprocal relationship from SPRO graph: were fully constrained as of December 31, 2024 and not included in the transaction price. The Company can also earn s…
VRTX Vertex Pharmaceuticals Incorporated 72% were fully constrained as of December 31, 2024 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuant to Amendment 2 to the GSK License Agreement, the Co…

Spero Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SPRO-DEBT Debt stack $2.5M 90% Market cache reports total debt of $2.5M.
SPRO-DEBT-12711 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.

Spero Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Spero Therapeutics, Inc..

Spero Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
SPRO-OWNER-GSK-PLC GSK plc 90% 13F overlay lists GSK plc as top holder; 51 tracked holders.

Spero Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
JBIO Jade Biosciences, Inc. 100.00 2
HALO Halozyme Therapeutics, Inc. 100.00 2
MRNA Moderna, Inc. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
ARVN Arvinas, Inc. 100.00 2
CRSP CRISPR Therapeutics AG 100.00 2
GSK GSK plc 100.00 1 ['customer']
TRDA Entrada Therapeutics, Inc. 100.00 2
CLYM Climb Bio, Inc. 100.00 2
COLL Collegium Pharmaceutical, Inc. 100.00 2
PFIZER PFIZER 60.75 1 ['receiving']
PFE Pfizer Inc. 60.75 1 ['customer']
HBIO Harvard Bioscience, Inc. 50.00 2
BCAX Bicara Therapeutics Inc. 50.00 2
DEO Diageo plc 50.00 2
TRVI Trevi Therapeutics, Inc. 50.00 2
HLN Haleon plc 50.00 2
ORANY ORANGE 50.00 2
TBPH Theravance Biopharma, Inc. 50.00 2
FULC Fulcrum Therapeutics, Inc. 50.00 2
View SPRO supply chain intel →

Explore the full interactive supply chain map for Spero Therapeutics, Inc..

Open SPRO supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map